Lilly Asia Ventures logo

Lilly Asia Ventures

Crunchbase
Pitchbook
Crunchbase

Deals on record

8

Common Fundraising Type

Series A

PAQ Therapeutics logo
PAQ Therapeutics

Biotechnology • Clinical Development

Sherpa Health Partners logo
MRL Ventures Fund logo
LAV Fund logo
Johnson & Johnson Innovation logo

PAQ Therapeutics is a biotechnology company focused on developing KRAS degrader therapies for treating lethal cancers.

Series B
$39M
05/07/2025
Article
EnChannel Medical logo
EnChannel Medical

Cardiac electrophysiology • Atrial fibrillation

EnChannel Medical develops a platform combining magnetic-impedance navigation and pulsed-field ablation to treat atrial fibrillation.

Series B
$82.5M
05/01/2025
Article
Pulnovo Medical logo
Pulnovo Medical

Medtech • Pulmonary hypertension

Qiming Venture Partners logo
OrbiMed logo
Lilly Asia Ventures logo
Gaorong Capita logo

Pulnovo Medical develops medical devices for treating pulmonary hypertension and heart failure, with a focus on their PADN technology.

Series C
$100M
03/03/2025
Article
Timberlyne Therapeutics logo
Timberlyne Therapeutics

Biopharmaceutical • Clinical-stage

Venrock Healthcare Capital Partners logo
Lilly Asia Ventures logo
Braidwell logo
Boyu Capital logo

Timberlyne Therapeutics is a biopharmaceutical company developing novel therapies for autoimmune disorders, focusing on advancing a monoclonal antibody targeting CD38.

Series A
$180M
01/10/2025
Article
Verdiva Bio logo
Verdiva Bio

Biopharmaceutical • Obesity

General Atlantic logo
Forbion logo
RA Capital Management logo
OrbiMed logo

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders.

Series A
$411M
01/09/2025
Article
Avenzo Therapeutics logo
Avenzo Therapeutics

Biotechnology • Oncology

TF Capital logo
Surveyor Capital logo
SR One logo
Sofinnova Investments logo

Avenzo Therapeutics is a biotechnology company developing oncology therapies, including a CDK2 inhibitor for advanced solid tumors and HR+/HER2-negative metastatic breast cancer.

Series A
Undisclosed
11/19/2024
Article

Series B
$35M
10/03/2023
Article
Lynk Pharmaceuticals logo
Lynk Pharmaceuticals

Pharmaceuticals • Autoimmune Diseases

Lynk Pharmaceuticals is a clinical-stage company that specializes in the research and development of FIC and BIC drugs targeting autoimmune diseases, inflammation, and oncology, with a focus on developing second and third-generation JAK inhibitors.

Series C
$44.1M
09/21/2023
Article